| 000 | 01675 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516081246.0 | ||
| 264 | 0 | _c20120827 | |
| 008 | 201208s 0 0 eng d | ||
| 022 | _a1942-3268 | ||
| 024 | 7 |
_a10.1161/CIRCGENETICS.111.961417 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aParé, Guillaume | |
| 245 | 0 | 0 |
_aEffect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. _h[electronic resource] |
| 260 |
_bCirculation. Cardiovascular genetics _cApr 2012 |
||
| 300 |
_a250-6 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngina, Unstable _xcomplications |
| 650 | 0 | 4 |
_aAryldialkylphosphatase _xgenetics |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xdrug therapy |
| 650 | 0 | 4 | _aClopidogrel |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTiclopidine _xanalogs & derivatives |
| 700 | 1 | _aRoss, Stephanie | |
| 700 | 1 | _aMehta, Shamir R | |
| 700 | 1 | _aYusuf, Salim | |
| 700 | 1 | _aAnand, Sonia S | |
| 700 | 1 | _aConnolly, Stuart J | |
| 700 | 1 | _aFox, Keith A A | |
| 700 | 1 | _aEikelboom, John W | |
| 773 | 0 |
_tCirculation. Cardiovascular genetics _gvol. 5 _gno. 2 _gp. 250-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1161/CIRCGENETICS.111.961417 _zAvailable from publisher's website |
| 999 |
_c21577066 _d21577066 |
||